Stoke Therapeutics (NASDAQ:STOK) Posts Earnings Results, Beats Expectations By $0.05 EPS

Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings results on Tuesday. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05, Zacks reports. The business had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%.

Stoke Therapeutics Trading Up 0.2 %

Shares of Stoke Therapeutics stock traded up $0.02 during trading hours on Thursday, reaching $13.27. 280,079 shares of the company’s stock were exchanged, compared to its average volume of 760,807. The stock has a market cap of $698.64 million, a P/E ratio of -6.09 and a beta of 0.95. The company has a 50 day moving average of $13.24 and a two-hundred day moving average of $13.70. Stoke Therapeutics has a fifty-two week low of $3.77 and a fifty-two week high of $17.58.

Insider Buying and Selling

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on STOK. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Leerink Partners began coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. Wedbush restated an “outperform” rating and set a $17.00 target price on shares of Stoke Therapeutics in a report on Thursday, July 11th. Leerink Partnrs raised Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of “Buy” and a consensus target price of $20.83.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.